559 related articles for article (PubMed ID: 28804832)
1. Measuring Direct Oral Anticoagulants.
Gosselin RC; Douxfils J
Methods Mol Biol; 2017; 1646():217-225. PubMed ID: 28804832
[TBL] [Abstract][Full Text] [Related]
2. Direct oral anticoagulants: An update.
Franco Moreno AI; Martín Díaz RM; García Navarro MJ
Med Clin (Barc); 2018 Sep; 151(5):198-206. PubMed ID: 29295790
[TBL] [Abstract][Full Text] [Related]
3. Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'.
Eller T; Flieder T; Fox V; Gripp T; Dittrich M; Kuhn J; Alban S; Knabbe C; Birschmann I
Eur J Cardiothorac Surg; 2017 Apr; 51(4):624-632. PubMed ID: 28043992
[TBL] [Abstract][Full Text] [Related]
4. Anticoagulants: What is new and what is the standard?
Lesko LJ
Clin Pharmacol Ther; 2016 Aug; 100(2):126-8. PubMed ID: 27197625
[TBL] [Abstract][Full Text] [Related]
5. [Not Available].
Själander S; Själander A
Lakartidningen; 2018 Dec; 115():. PubMed ID: 30512136
[No Abstract] [Full Text] [Related]
6. Laboratory measurement of the direct oral anticoagulants.
Dale BJ; Chan NC; Eikelboom JW
Br J Haematol; 2016 Feb; 172(3):315-36. PubMed ID: 26492202
[TBL] [Abstract][Full Text] [Related]
7. Stability of direct oral anticoagulants in whole blood and plasma from patients in steady state treatment.
McGrail R; Revsholm J; Nissen PH; Grove EL; Hvas AM
Thromb Res; 2016 Dec; 148():107-110. PubMed ID: 27835819
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of dabigatran, rivaroxaban and apixaban target-specific assays in a multicenter French study.
Gouin-Thibault I; Freyburger G; de Maistre E; Susen S; Delavenne X; Golmard JL; Gruel Y; Sié P;
Thromb Res; 2017 Oct; 158():126-133. PubMed ID: 28892657
[TBL] [Abstract][Full Text] [Related]
9. Direct oral anticoagulants (DOACs).
Vazquez S; Rondina MT
Vasc Med; 2015 Dec; 20(6):575-7. PubMed ID: 26285587
[TBL] [Abstract][Full Text] [Related]
10. [Not Available].
Oldgren J
Lakartidningen; 2018 Dec; 115():. PubMed ID: 30512140
[No Abstract] [Full Text] [Related]
11. Measurement of Non-Vitamin K Antagonist Oral Anticoagulants in Patient Plasma Using Heptest-STAT Coagulation Method.
Du S; Harenberg J; Krämer S; Krämer R; Wehling M; Weiss C
Ther Drug Monit; 2015 Jun; 37(3):375-80. PubMed ID: 25525760
[TBL] [Abstract][Full Text] [Related]
12. Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants.
Testa S; Paoletti O; Legnani C; Dellanoce C; Antonucci E; Cosmi B; Pengo V; Poli D; Morandini R; Testa R; Tripodi A; Palareti G
J Thromb Haemost; 2018 May; 16(5):842-848. PubMed ID: 29532628
[TBL] [Abstract][Full Text] [Related]
13. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH.
Khorana AA; Noble S; Lee AYY; Soff G; Meyer G; O'Connell C; Carrier M
J Thromb Haemost; 2018 Sep; 16(9):1891-1894. PubMed ID: 30027649
[No Abstract] [Full Text] [Related]
14. Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review.
Eikelboom JW; Quinlan DJ; Hirsh J; Connolly SJ; Weitz JI
JAMA Cardiol; 2017 May; 2(5):566-574. PubMed ID: 28355459
[TBL] [Abstract][Full Text] [Related]
15. Using new oral anticoagulants in patients undergoing major orthopedic surgery.
Bass AR
Curr Rheumatol Rep; 2015 Apr; 17(4):25. PubMed ID: 25854486
[TBL] [Abstract][Full Text] [Related]
16. Multianalyte Determination of NOACs Using LC-MS/MS and Comparison with Functional Coagulation Assays.
Slavik L; Lukes J; Friedecky D; Zhanelova M; Nemcova M; Ulehlova J; Prochazkova J; Hlusi A; Palova M; Vaclavik J
Clin Lab; 2018 Oct; 64(10):1611-1621. PubMed ID: 30336535
[TBL] [Abstract][Full Text] [Related]
17. [Not Available].
Strandberg K
Lakartidningen; 2018 Dec; 115():. PubMed ID: 30512144
[No Abstract] [Full Text] [Related]
18. Direct oral anticoagulant plasma levels' striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: The Cremona experience.
Testa S; Prandoni P; Paoletti O; Morandini R; Tala M; Dellanoce C; Giorgi-Pierfranceschi M; Betti M; Danzi GB; Pan A; Palareti G
J Thromb Haemost; 2020 Jun; 18(6):1320-1323. PubMed ID: 32329231
[TBL] [Abstract][Full Text] [Related]
19. Limitations of Specific Coagulation Tests for Direct Oral Anticoagulants: A Critical Analysis.
Ebner M; Birschmann I; Peter A; Härtig F; Spencer C; Kuhn J; Rupp A; Blumenstock G; Zuern CS; Ziemann U; Poli S
J Am Heart Assoc; 2018 Oct; 7(19):e009807. PubMed ID: 30371316
[TBL] [Abstract][Full Text] [Related]
20. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.
Graff J; Harder S
Clin Pharmacokinet; 2013 Apr; 52(4):243-54. PubMed ID: 23389892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]